Abbvie Inc
Exchange: NYSESector: HealthcareIndustry: Drug Manufacturers - General
AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas including immunology, neuroscience and oncology – and products and services in our Allergan Aesthetics portfolio.
Did you know?
Generated $14.7 in free cash flow for every $1 of capital expenditure in FY25.
Current Price
$208.84
-2.86%GoodMoat Value
$131.68
36.9% overvaluedProfile
Valuation (TTM)
Market Cap$369.10B
P/E87.34
EV$424.43B
P/B—
Shares Out1.77B
P/Sales6.04
Revenue$61.16B
EV/EBITDA24.85
Abbvie Inc (ABBV) Stock Analysis
GoodMoat Analysis
AbbVie is a major pharmaceutical company with a strong moat built on patents and a powerful brand, but it currently trades at a significant premium to its estimated fair value. The GoodMoat Target of $131.68 suggests the stock is unfavourable from a value perspective. A deeper look is required to assess the durability of its moat post-Humira and the justification for its high P/E multiple.
Read full analysis
AbbVie is a global pharmaceutical company known for its immunology and oncology portfolio, most famously the blockbuster drug Humira. Applying the GoodMoat framework, the company demonstrates a strong competitive moat (likely scoring high in Section 1 criteria such as Regulatory Barriers via patents, Brand & Culture, and Pricing Power). However, the key investment question revolves around the durability of this moat as Humira faces biosimilar competition, and the ability of its newer drugs (Skyrizi, Rinvoq) to fill the gap. Financially, the data shows mixed signals: a solid 10.0% YoY revenue growth and a 24.6% operating margin indicate a quality business, but a profit margin of only 6.9% and a high P/E of 86.6 suggest significant earnings pressure or one-time charges. The 4.9% FCF yield is reasonable but not exceptional for a value investor. The Decision Framework (Section 6) highlights a critical valuation concern: the current price of $207.18 is approximately 57% above the provided GoodMoat Target of $131.68, indicating no margin of safety and placing it in the 'Unfavourable' valuation band. While the business itself possesses a moat, the extreme premium to estimated intrinsic value makes it an unfavourable candidate for a value-oriented purchase without a substantial price correction or significantly improved earnings outlook.
Market Cap$369.10B
Current Price$208.84
P/E Ratio87.34
Forward P/E—
PEG Ratio-0.01
EPS$2.36
Book Value$-1.85
P/B Ratio—
ABBV Financial Charts
FCF vs CAPEX
FCFCAPEX
Forward estimates use 5.7% FCF growth (CAGR)
Cash vs Debt
Net Debt: 62.3B
Revenue
33.3B
FY19
45.8B
FY20
56.2B
FY21
58.1B
FY22
54.3B
FY23
56.3B
FY24
61.2B
FY25
Net Income
7.9B
FY19
4.6B
FY20
11.5B
FY21
11.8B
FY22
4.9B
FY23
4.3B
FY24
4.2B
FY25
ABBV 52-Week Range
$166.12
$240.68
50-Day MA: $221.60200-Day MA: $214.15
Did you know?
A mega-cap stock valued at $369B.
Abbvie Inc (ABBV) Financial Summary
Abbvie Inc (ABBV) is a Healthcare company in the Drug Manufacturers - General industry, listed on NYSE. The stock currently trades at $208.84 with a market capitalization of $369.10B.
Key valuation metrics include a P/E ratio of 87.34, and EPS of $2.36. The company reports a profit margin of 6.9%.
ABBV Key Financial Metrics
| Metric | Value |
|---|---|
| Market Cap | $369.10B |
| P/E Ratio | 87.34 |
| EPS | $2.36 |
| P/S Ratio | 6.04 |
| EV/EBITDA | 24.85 |
| Dividend Yield | 3.16% |
| Profit Margin | 6.9% |
ABBV Revenue & Earnings History
| Year | Revenue | Net Income |
|---|---|---|
| FY19 | $33.27B | $7.88B |
| FY20 | $45.80B | $4.62B |
| FY21 | $56.20B | $11.54B |
| FY22 | $58.05B | $11.84B |
| FY23 | $54.32B | $4.86B |
| FY24 | $56.33B | $4.28B |
| FY25 | $61.16B | $4.23B |
Abbvie Inc (ABBV) Valuation
Based on GoodMoat's DCF model, Abbvie Inc has a fair value estimate of $131.68. At the current price of $208.84, the stock appears 58.6% overvalued relative to our intrinsic value estimate.
ABBV Quality Indicators
Abbvie Inc maintains a profit margin of 6.9% and an operating margin of 24.6%. The current ratio is 0.67.
About Abbvie Inc
AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas including immunology, neuroscience and oncology – and products and services in our Allergan Aesthetics portfolio.
ABBV Free Cash Flow
Abbvie Inc generated $17.82B in trailing twelve-month free cash flow, representing an FCF yield of 4.83%. This moderate FCF yield indicates reasonable cash generation.
ABBV Shares Outstanding
Abbvie Inc has 1.77 billion shares outstanding at a share price of $208.84, giving it a market capitalization of $369.10B.
ABBV Recent Insider Trades
Recent insider transactions at Abbvie Inc include:
| Insider | Type | Shares | Value |
|---|---|---|---|
| Purdue David Ryan (SVP, Controller) | SELL | 5,230 | $1.22M |
| Siatis Perry C (EVP, GC AND SECRETARY) | SELL | 5,777 | $1.35M |
| Siatis Perry C (EVP, GC AND SECRETARY) | SELL | 22,381 | $5.15M |